PHILADELPHIA, PA (April 1, 2016): Earlier this week, the U.S. Food and Drug Administration announced new guidelines for prescribing Mifepristone, a drug used for medication abortion.  Melissa Weiler Gerber, President and CEO of AccessMatters released the following statement:

“AccessMatters supports the U.S. Food and Drug Administration’s new guidelines which will expand access to medication abortion.  As a public health advocate and Title X safety-net provider, AccessMatters is committed to ensuring women are able to exercise a full range of reproductive health options, including prenatal care and delivery; foster care; adoption; and abortion services. AccessMatters works to ensure providers are trained to deliver unbiased pregnancy options counseling in safe, confidential settings.  The FDA’s decision to reduce the number of visits to a healthcare provider needed to access the medication, to extend the period of time into a pregnancy that a woman can take the medication, and to reduce the dosage needed, all align with standard medical practice.  This decision is a victory for science over politics and for all women nationwide.”


 Download AccessMatters’ Statement on the FDA Decision.

Pin It on Pinterest

Share This